Skip to content

Study · Randomized controlled trial · n = 85 · 2020

3 results

Metabolic changes with degarelix vs leuprolide plus bicalutamide in patients with prostate cancer: a randomized clinical study.

Sawazaki H, Araki D, Kitamura Y, Yagi K

World journal of urology3 Sept 2019Cited by 8 (Europe PMC)

PMID31482294 (opens in a new tab)DOI10.1007/s00345-019-02937-x (opens in a new tab)PepBankPUB-31482294
Publisher pagePubMedAsk about this study
Jump to 3 results

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: Publisher copyright. Results still quote short attributed sentences.

Results from this study3

3 results from studies that gave the peptide. 3 results from people.

  1. 01HumanRandomized controlled trialEfficacy outcome

    In hormone-naive prostate cancer, mean fasting blood sugar increases did not differ between degarelix and leuprolide plus bicalutamide.

    In plain wordsIn hormone-naive prostate cancer, fasting blood sugar increases did not differ between degarelix and leuprolide plus bicalutamide.

    Peptide
    Degarelix
    Outcome
    No significant changeFasting blood sugar increase
    Study

    n = 85

    Comparator
    Leuprolide plus bicalutamide
    Analysis
    Primary
    Outcome group
    Glycemic control · Metabolic and weight
    Studied dose
    Dose not stated · 6 monthsAs given in this study (human).

    Source sentences

    Summary
    Mean increases in FBS did not differ between the two arms.
    3 context sentences
    Summary · context
    Patients with hormone-naive PCa were recruited.
    Summary · context
    Eligible patients were randomized (1:1) to monthly degarelix or monthly leuprolide for 6 months.
    Title · context
    Metabolic changes with degarelix vs leuprolide plus bicalutamide in patients with prostate cancer: a randomized clinical study.
  2. 02HumanRandomized controlled trialEfficacy outcome

    In hormone-naive prostate cancer, increases in weight, waist circumference, lipids, HbA1c, and fat areas did not differ between degarelix and leuprolide plus bicalutamide.

    In plain wordsIn hormone-naive prostate cancer, secondary metabolic changes did not differ between degarelix and leuprolide plus bicalutamide.

    Peptide
    Degarelix
    Outcome
    No significant changeSecondary metabolic measures
    Study

    n = 85

    Comparator
    Leuprolide plus bicalutamide
    Analysis
    Secondary
    Outcome group
    Cardiometabolic risk factors · Metabolic and weight
    Studied dose
    Dose not stated · 6 monthsAs given in this study (human).

    Source sentences

    Summary
    Similarly, there were no differences between the arms in mean increases in body weight, abdominal circumference, lipid profiles, HbA1c, or subcutaneous and visceral fat areas.
    3 context sentences
    Summary · context
    Patients with hormone-naive PCa were recruited.
    Summary · context
    Eligible patients were randomized (1:1) to monthly degarelix or monthly leuprolide for 6 months.
    Title · context
    Metabolic changes with degarelix vs leuprolide plus bicalutamide in patients with prostate cancer: a randomized clinical study.
  3. 03HumanRandomized controlled trialEfficacy outcome

    In hormone-naive prostate cancer, follicle-stimulating hormone was lower with degarelix than leuprolide plus bicalutamide (p < 0.05).

    In plain wordsIn hormone-naive prostate cancer, follicle-stimulating hormone was lower with degarelix than with leuprolide plus bicalutamide.

    Peptide
    Degarelix
    Outcome
    DecreaseFollicle-stimulating hormone
    Study

    n = 85

    Comparator
    Leuprolide plus bicalutamide
    Analysis
    Secondary
    Outcome group
    Sex hormones and fertility · Endocrine and hormones
    Studied dose
    Dose not stated · 6 monthsAs given in this study (human).

    Source sentences

    Summary
    Follicle-stimulating hormone levels were significantly lower in the degarelix arm than in the leuprolide arm (p < 0.05).
    3 context sentences
    Summary · context
    Patients with hormone-naive PCa were recruited.
    Summary · context
    Eligible patients were randomized (1:1) to monthly degarelix or monthly leuprolide for 6 months.
    Title · context
    Metabolic changes with degarelix vs leuprolide plus bicalutamide in patients with prostate cancer: a randomized clinical study.

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

  1. Version 2Current

    28 Oct 2026, 02:03 UTC

    Study results updated

  2. Version 1

    27 Oct 2026, 16:34 UTC

    First added · source update from Europe PMC

Subjects

Terms as the source lists them.

PepBank is a research reference. Talk to a doctor before you use any peptide.